COVID-19 Protein Found to Speed Toxic Alpha-Synuclein Buildup

Patricia Inacio PhD avatar

by Patricia Inacio PhD |

Share this article:

Share article via email
Sigma-2 Receptor | Parkinson's News Today | illustration of scientist in lab

A protein present in the SARS-CoV-2 virus — the virus that causes COVID-19 — is able to interact with alpha-synuclein and speed the formation of amyloid fibrils, the toxic clumps that trigger nerve cells death and are a hallmark of Parkinson’s disease, a study has shown.

“We show, in test tube experiments, that … SARS-CoV-2 nucleocapsid protein (N-protein) considerably speeds up the aggregation process,” the researchers wrote. N-protein is one of the virus’ two most abundant proteins.

These findings highlight the potential long-term implications of COVID-19 and could help explain a possible link between COVID-19 and Parkinson’s disease, according to researchers.

The study, “Interactions between SARS-CoV-2 N-Protein and α-Synuclein Accelerate Amyloid Formation,” was published in the journal ACS Chemical Neuroscience.

Recommended Reading
COVID-19 and Parkinson's

COVID-19 Poses Greater Risk to Hospitalized Patients

Infection with SARS-CoV-2 affects primarily the lungs but also other organs, including the brain. As a result, some patients have reported neurological symptoms, including headaches, “brain fog” and loss of smell — also a common early non-motor symptom of Parkinson’s disease.

However, whether these symptoms are triggered by the virus once it reaches the brain, or are instead a consequence of the immune system’s reaction remains controversial.

Recent case reports of relatively young people who developed Parkinson’s after contracting COVID-19 suggest a potential link between both diseases.

Now, a team of researchers investigated whether protein components of the SARS-CoV-2 virus that causes COVID-19 could trigger the formation of toxic protein clumps called amyloid fibrils. A hallmark of Parkinson’s disease, the key component of these clumps is the alpha-synuclein protein.

Researchers studied the two most abundant proteins in the virus: the spike (S-) protein that helps the virus enter cells, and the nucleocapsid (N-) protein that composes the viral capsid (shell) with its genomic information.

In vitro or laboratory tests were conducted in which the amyloid fibrils were linked to a fluorescent probe to make them visible and easy to track.

In the absence of any COVID-19-related viral protein, the alpha-synuclein protein took more than 240 hours — longer than 10 days — to aggregate into amyloid fibrils. No new effects were seen when the researchers added the viral S-protein.

However, with the viral N-protein, the team found that alpha-synuclein formed fibrils in less than 24 hours, or within one day.

“In the presence of N-protein, the onset of [alpha-synuclein] aggregation into amyloid fibrils is strongly accelerated, indicating that N-protein facilitates the formation of a critical nucleus for aggregation,” the researchers wrote.

Further experiments showed that the viral N-protein and alpha-synuclein interacted directly, with at least three to four copies of alpha-synuclein bound to each N-protein.

Next, human neural cells called SH-SY5Y, a standard cellular model to study neurodegenerative disorders, were injected with the N-protein and fluorescently labeled alpha-synuclein. The N-protein was injected at a concentration similar to that expected inside a SARS-CoV-2-infected cell.

The rate of dead cells was double for those that had received both proteins compared with cells that were injected with alpha-synuclein alone and that served as controls.

The distribution of alpha-synuclein was also different, with cells injected with both proteins showing more elongated, fibril-like structures. The researchers, however, could not confirm that they were amyloid fibrils.

Overall, “our results point toward a direct interaction between the N-protein of SARS-CoV-2 and αS [alpha-synuclein] as a molecular basis for the observed relations between virus infections and Parkinsonism,” the researchers wrote.

These interactions “suggest that SARS-CoV-2 infections may have long-term implications and that caution is required in considering N-protein as an alternative target in vaccination strategies,” they added.

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums